O.A. SAVVATEEVA¹, A.V. GORELOV^{1, 3}, D.V. PECHKUROV², A.A. TYAZHEVA²

 ¹First Moscow State Medical University (Sechenov University), Moscow

²Samara State Medical University, Samara

³Central Research Institute of Epidemiology under the Federal Supervision Service for Consumer Rights Protection and Human Welfare, Moscow

Contact details:

Pechkurov Dmitry V. — MD, Professor, Head of the Department of Children’s Diseases

Address: 89 Chapaevskaya St., 443099 Samara, Russian Federation, tel.: +7 (846) 959-45-11, e-mail: dmpechkurov@yandex.ru

SARS-CoV-2 infection often leads to coagulation disorders such as hypercoagulation and thrombotic microangiopathy. In children, these changes may be asymptomatic. It is relevant to study the duration of these changes in hemostasis after the clinical manifestations of COVID-19 are resolved.

The purpose — to assess the frequency and duration of hypercoagulation in children with IBD after COVID-19.

Material and methods. 60 children with IBD after COVID-19 were examined. The comparison group included 30 children with IBD who had not been infected with coronavirus. We performed a standard laboratory and instrumental examination and determined the number of platelets, fibrinogen levels, activated partial thromboplastin time, prothrombin time, Quick prothrombin index, and blood D-dimer.

Results. During the first three months after the COVID-19 infection, there were pronounced hemostatic disorders. The APTT and PT values were significantly reduced in children with IBD who had had COVID-19 compared to those who had not. In the main group, there was a significant increase in the D-dimer level. In total, 22 children (45.8%) were found to have hypercoagulation in the early post-COVID period, based on at least one of the parameters studied.

Conclusions. The hypercoagulation induced by the infection developed and persisted for 3 months in almost half of the children (45.8%), then the proportion of such children progressively decreased and by the end of the first year of the post-infection period, all indicators, except for the D-dimer level, were normalized.

Key words: hypercoagulation, COVID-19, SARS-CoV-2, inflammatory bowel diseases.

REFERENCES

1. Zadumina D.N., Skvortsov V.V. Changes in hematological parameters in COVID-19. Lechashchiy vrach, 2022, no. 11 (in Russ.), available at: https://www.lvrach.ru/2022/11/15438503 (accessed on: 22.11.2022).
2. Zheng R., Zhou J., Song B., Zheng X., Zhong M., Jiang L. et al. COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU. Exp. Hematol. Oncol, 2021, vol. 10, article 6.
3. Shatokhin Yu.V., Snezhko I.V., Ryabkina E.V. Impaired hemostasis in coronavirus infection. Yuzhno-Rossiyskiy zhurnal terapevticheskoy praktiki, 2021, vol. 2, no. 2 (in Russ.). DOI: 10.21886/2712-8156-2021-2-2-6-15
4. Boyarchuk O., Perestiuk V., Kosovska T., Volianska L. Coagulation profile in hospitalized children with COVID-19: pediatric age dependency and its impact on long COVID development. Front. Immunol, 2024, vol. 15. 1363410. DOI: 10.3389/fimmu.2024.1363410
5. Fox Sh.E., Akmatbekov A., Harbert J.L., Li G., Brown J.Q., Vander Heide R.S. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Resp. Med, 2020, vol. 8 (7), pp. 681–686. DOI: 10.1016/s2213-2600(20)30243-5
6. Buonsenso D., Munblit D., De Rose C. et al. Preliminary evidence on long COVID in children. Acta Paediatr, 2021, vol. 110 (7), pp. 2208–2211. DOI: 10.1111/apa.15870
7. Yevseyeva G.P., Telepneva R.S., Knizhnikova E.V., Suprun S.V., Pichugin S.V., Yakovlev E.I. et al. COVID-19 in the pediatric population. Byulleten′ fiziologii i patologii dykhaniya, 2021, vol. 80, pp. 100–114 (in Russ.). DOI: 10.36604/1998-5029-2021-80-100-114
8. Wei-Jie Guan, Zheng-Yi Ni, Yu Hu, Wen-Hua Liang, Chun-Quan Ou, Jian-Xing He. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med, 2020, vol. 382 (18), pp. 1708–1720. DOI: 10.1056/NEJMoa2002032
9. Liao D., Zhou F., Luo L., Xu M., Wang H., Xia J. et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort. Lancet Haematol, 2020, vol. 7 (9), pp. e671–e678. DOI: 10.1016/S2352-3026(20)30217-9
10. Amgalan A., Othman M. Exploring possible mechanisms for COVID-19 induced thrombocytopenia: Unanswered questions. J. Thromb. Haemost, 2020, vol. 18 (6), pp. 1514–1516. DOI: 10.1111/jth.14832
11. Chen W., Li Z., Yang B., Wang P., Zhou Q., Zhang Z. et al. Delayed-phase thrombocytopenia in patients with coronavirus disease 2019 (COVID-19). Br. J. Haematol, 2020, vol. 190 (2), pp. 179–184. DOI: 10.1111/bjh.16885
12. Mei H., Luo L., Hu Y. Thrombocytopenia and thrombosis in hospitalized patients with COVID-19. J. Hematol. Oncol, 2020, vol. 13, article 161.
13. Fogarty H., Townsend L., Morrin H., Ahmad A., Comerford C., Karampini E. et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J. Thromb. Haemost., 2021, vol. 19 (10), pp. 2546–2553. DOI: 10.1111/ jth.15490
14. Goshua G., Pine A., Meizlish M., Chang C., Zhang H., Bahel P. et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol, 2020, vol. 7 (8), pp. e575–e582. DOI: 10.1016/S2352- 3026 (20)30216-7
15. Kovtun O.P., Olen′kova A.V., Leont′yeva A.V. Coagulopathy in children with COVID-19: features of the acute period of the disease and long-term consequences. Permskiy meditsinskiy zhurnal, 2024, vol. XLI, pp. 43–55 (in Russ.).
16. Voronko N.V., Dmitriyev V.V. Blood clotting in COVID-19 infection that complicated the treatment of children with hemoblastoses. Gematologiya. Transfuziologiya. Vostochnaya Yevropa, 2021, vol. 7, no. 4, pp. 417–424 (in Russ.). DOI: 10.34883/ Pl.2021.7.4.002